NCT00684515View on ClinicalTrials.gov

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 21, 2006

Primary Completion Date

November 8, 2007

Study Completion Date

November 8, 2007

Conditions
Cerebral Infarction
Interventions
DRUG

Vorapaxar 2.5 mg

Oral tablets; once daily for 60 days.

DRUG

Vorapaxar 1 mg

Oral tablets; once daily for 60 days

DRUG

Placebo

oral tablets; once daily for 60 days

DRUG

Aspirin 75-150 mg

oral tablets; once daily for 60 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00684515 - Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) | Biotech Hunter | Biotech Hunter